Do you want to link to our other external sites and leave Amgen.ca?
You are now leaving the Amgen Canada website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.
You are now leaving the Amgen.ca website.
The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk
Amgen has built an organization distinguished by world-class scientists with a talent for applying novel approaches to treat disease. Our R&D strategy aims to align and engage our talent, prioritize investments, and seize scientific opportunities.
With the union of technology and biotechnology, we are at a hinge moment in drug discovery and development. Amgen's scientific success is rooted in unique capabilities that include:
To design better biologics more quickly and effectively.
We are at a hinge moment in the biopharmaceutical industry, where we are seeing profound changes in drug discovery and development powered by the union of technology and biotechnology. At Amgen we have been preparing for this moment for over a decade, investing in the power of artificial intelligence (AI), data science and other technologies to create the next generation of medicines that will bring the most value to patients.
The sophistication of drug discovery has evolved. Generative Biology and the convergence of machine learning, AI technology and biology reimagines the protein drug discovery process. Amgen is exploring this new wave of innovation to predict protein structures and reduce discovery timelines with the goal of increasing success rates. Leveraging biology insights, AI and machine learning we are moving from the idea of a protein to a medicine.
To drug the undruggable by engaging one or more targets at once. Multispecific medicines have the potential to radically alter our concept of how drugs work and pave the way for new therapies. We built our Induced Proximity Platform to identify multispecific molecules that induce proximity to enable the modulation of a target.
These multispecifics harness the power of cell biology by using a built-in "address label" to concentrate their impact where it is most needed, or by acting as "molecular matchmakers" to link a disease-causing target to potent natural mechanisms in our bodies that act upon that target. We believe multispecifics and other modalities are leading the next wave of drug discovery.
Conventional medicines are produced to target a protein and attach that protein to alter its activity. Today, many diseases have proteins too big or too complex that are hard to tackle with conventional drugs. This is evolving toward a new approach in drug design called multi specifics. Multi Specifics use an induced proximity process to bring together a disease target and an effector. It acts on that target, or it uses built in zip codes that deliver the drug to its site of action. Multispecifics are shaping the future of medicine in the biopharmaceutical industry to fight against diseases considered untreatable. They’re using the body’s natural biological mechanisms to reach targets which were considered out of reach previously.
To speed up and improve trials using the latest technologies. At Amgen, we are innovating clinical trials in ways that are improving our understanding of the natural course of disease as well as our ability to predict patient responses to the new medicines in development.
The result? Shorter, smaller, more accessible studies that will yield more valuable data so we can make faster decisions and get more new, safe and effective medicines to the patients who are most likely to benefit.
Amgen is innovating new ways to get medicines to patients faster. To achieve that, our R&D strategy in clinical trials is focused on leveraging innovative clinical trials design, real world data and digital technologies to accelerate drug development. We are continuously working to achieve equitable access to clinical trials by improving the diversity of participants in a study and ensuring they are more characteristic of a broader patient population. Adaptive clinical trials allow continual learning as data is being collected, helping to find new solutions for those who are afflicted with the disease we seek to treat. We are now evolving the way we think and run clinical trials applying new approaches in design and execution to improve efficiency and flexibility and to increase speed.
To advance precision medicine and better understand human diversity and disease using genomics, omics and other data.
We are now in the 'era of human data,' a transformative opportunity for drug discovery and development. Going well beyond genetics, human data includes significant advances in computational techniques and multi-omics, which includes genomics, transcriptomics, and proteomics, plus a tsunami of real- world data and real- world evidence from electronic health records, insurance claims data bases and many other sources. Insights from human data will help us improve understanding of disease prediction, identify new targets, as well as find the right patient populations for the next generation of first-in-class therapeutics.
At Amgen we believe greater understanding can be found by delving deeper into our DNA. The huge growth of biological data and computational technologies are allowing scientists to perform a wide range of analysis in a much more rapid and cost-effective way than previously possible, even just 20 years prior. Data science is also changing the way researchers can understand, diagnose, and track diseases for the next generation of first-in-class therapeutics. deCODE, our Icelandic subsidiary, is leading the way in collection and analysis of genomics and to find meaningful insights by applying a multi-omics approach. The use of omics in drug development allows us to deliver transformative therapies.